Company Quick10K Filing
Axim Biotechnologies
10-K 2019-12-31 Filed 2020-05-14
10-Q 2019-09-30 Filed 2019-11-14
10-Q 2019-06-30 Filed 2019-08-14
10-Q 2019-03-31 Filed 2019-05-15
10-K 2018-12-31 Filed 2019-04-08
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-14
10-Q 2018-03-31 Filed 2018-05-15
10-K 2017-12-31 Filed 2018-03-15
10-Q 2017-09-30 Filed 2017-11-20
10-Q 2017-06-30 Filed 2017-08-21
10-Q 2017-03-31 Filed 2017-05-22
10-K 2016-12-31 Filed 2017-04-17
10-Q 2016-09-30 Filed 2016-11-21
10-Q 2016-06-30 Filed 2016-08-22
10-Q 2016-03-31 Filed 2016-05-23
10-K 2015-12-31 Filed 2016-04-14
10-Q 2015-09-30 Filed 2015-11-23
10-Q 2015-06-30 Filed 2015-08-19
10-Q 2015-03-31 Filed 2015-05-13
10-K 2014-12-31 Filed 2015-04-14
10-Q 2014-09-30 Filed 2014-11-14
10-Q 2014-06-30 Filed 2014-08-19
10-Q 2014-03-31 Filed 2014-05-20
10-K 2013-12-31 Filed 2014-03-04
10-Q 2013-09-30 Filed 2013-11-18
10-Q 2013-06-30 Filed 2013-08-14
10-Q 2013-03-31 Filed 2013-05-15
10-K 2012-12-31 Filed 2013-04-15
10-Q 2012-09-30 Filed 2012-11-19
10-Q 2012-06-30 Filed 2012-08-14
10-Q 2012-03-31 Filed 2012-05-17
10-K 2011-12-31 Filed 2012-04-16
10-Q 2011-09-30 Filed 2011-11-17
8-K 2020-05-14 Other Events
8-K 2020-05-13 Regulation FD, Other Events, Exhibits
8-K 2020-05-06 Enter Agreement, M&A, Off-BS Arrangement, Sale of Shares, Officers
8-K 2020-03-27 Other Events
8-K 2020-03-17 Enter Agreement, M&A, Sale of Shares, Regulation FD, Exhibits
8-K 2020-01-03 Enter Agreement, Regulation FD, Exhibits
8-K 2019-12-16 Enter Agreement, Exhibits
8-K 2019-07-02 Enter Agreement, Regulation FD, Exhibits
8-K 2019-05-31 Enter Agreement, Regulation FD, Exhibits
8-K 2019-04-19 Enter Agreement, Regulation FD, Exhibits
8-K 2019-04-02 Officers, Regulation FD, Exhibits
8-K 2019-02-20 Control, Exhibits
8-K 2019-01-15 Regulation FD, Exhibits
8-K 2019-01-02 Officers, Regulation FD, Exhibits
8-K 2018-11-30 Enter Agreement, Exhibits
8-K 2018-09-10 Enter Agreement, Regulation FD, Exhibits
8-K 2018-08-21 Enter Agreement, Regulation FD, Exhibits
8-K 2018-05-07 Enter Agreement
8-K 2018-04-05 Enter Agreement, Regulation FD, Exhibits
8-K 2018-03-30 Enter Agreement, Exhibits

Axim Biotechnologies Financials

AXIM Metrics, Comps, Filings

Quarterly | Annual

Business

Axim Biotechnologies, Inc., a Nevada corporation, is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products, and extraction and purification of cannabinoids technologies based on our proprietary technologies. We believe to be setting the standard for cannabinoid bioscience through the discovery and commercialization of new materials and technologies for healthy living. Our common stock is traded on the OTCQB under the symbol "AXIM."

We were originally incorporated in the State of Nevada on November 18, 2010 under the name AXIM International, Inc. On July 24, 2014, we changed our name to AXIM Biotechnologies, Inc. to better reflect our business operations. On August 7, 2014, we incorporated a wholly owned Nevada subsidiary named Axim Holdings, Inc. to help facilitate the business operations of the Company.

On May 11, 2015, we entered into a 50 year, worldwide, exclusive intellectual property licensing agreement ("Agreement") with CanChew Biotechnologies, LLC ("CanChew"). As compensation for the Agreement, CanChew received 5,826,706 restricted shares of the Company's common stock and a royalty fee of approximately 2-3% of all gross sales derived from products produced under the Agreement. So long as we are in compliance with the Agreement, we have the option to purchase the licensed intellectual property after 5 years at a purchase price equal to fifty percent (50%) of the annual royalty fee paid.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Equity

Income Statement ($MM Quarterly)

Revenue, G Profit, Net Income

Cash Flow ($MM Quarterly)

Ops, Inv, Fin

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Netlist (NLST) 49,311 8% -3.8 -88% 17,046 28,756 25,754 1,987 -15,063 -14,932 57,337
Pilgrim Bancshares (PLRM) 48,672 -255% 7.2 0% 265,062 230,554 66 -168 1,054 4,999 36,220
Invo Bioscience (IVOB) 48,235 90% -44.5 -55% 2,565 6,325 1,152 1,040 -1,410 -1,039 46,225
Axim Biotechnologies (AXIM) 45,833 18% -9.2 -211% 2,377 8,554 513 95 -5,011 -4,838 44,666
Hickok (HICKA) 45,489 22% 4.7 11% 62,836 43,919 89,731 19,505 6,620 10,751 50,895
PayMeOn (PAYM) 45,400 -1,762% -13.7 -131% 2,583 3,294 4 -69 -3,373 -3,295 45,135
Arch Therapeutics (ARTH) 45,130 -9.4 -157% 2,902 3,710 0 0 -4,548 -4,548 42,950
Positive Physicians Holdings (PPHI) 44,543 0% 148.2 -0% 154,581 81,735 20,883 0 -474 174 25,856
Intersections (INTX) 44,437 68% 4.2 25% 37,736 36,881 155,171 105,871 9,357 13,535 56,883
Petroshare (PRHR) 44,347 0% 5.6 -15% 36,928 45,101 16,134 0 -5,501 7,311 40,589
Medicine Man Technologies (MDCL) 44,094 40% -2.1 -38% 35,919 7,979 9,100 3,629 -13,562 -13,517 28,889
Terra Tech (TRTC) 44,034 50% -2.4 -23% 129,806 38,597 25,337 12,769 -29,554 -23,775 57,216
Hoth Therapeutics (HOTH) 44,012 -10.7 -88% 4,335 25 0 0 -3,793 -3,793 40,597
Cosmos Holdings (COSM) 43,856 7% 120.0 -1% 21,280 27,665 36,392 2,689 -183 380 45,596
Gulfslope Energy (GSPE) 43,691 -3.7 -45% 30,784 31,113 0 0 -13,724 -11,439 42,552
Solis Tek (SLTK) 43,678 51% -25.8 -163% 1,378 6,785 1,895 973 -2,244 -1,693 43,612
Where Food Comes From (WFCF) 43,107 42% 21.1 4% 19,538 6,989 15,075 6,341 759 1,882 39,712
CCUR (CCUR) 42,638 0% 7.9 6% 65,998 9,965 5,021 0 4,245 4,508 35,471
Smartag International (SMRN) 42,619 100% -140.1 -347% 87 31 1 1 -304 -304 42,532
Mastermind (MMND) 42,338 88% 91.3 16% 2,419 256 3,727 3,297 375 459 41,906

Balance Sheet ($'000)2011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-09-302014-12-312015-03-312015-09-302017-03-312017-06-302017-09-302017-12-312018-09-302018-12-312019-03-312019-06-302019-09-30
Cash2339281914010950661195436324,1043,0822,0586321,8062,6622,2081,167
Accounts Receivable1015202015111339
Inventory2359641793107885466
PP&E16111110966543
Assets728758681331269691571,0627382361,8258254,4143,3222,1927922,0893,0182,8822,377
Accounts Payable6
Long-Term Debt462,818
Liabilities627749561381361371421511,2511,3191,2872,5883,7217,8428,1748,4776,9948,1718,3059,0438,554
Stockholders' Equity1010912-5-11-40-51-94-189-581-1,052-763-2,896
Income Statement ($'000)2011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-09-302014-12-312015-03-312015-09-302017-03-312017-06-302017-09-302017-12-312018-09-302018-12-312019-03-312019-06-302019-09-30
Revenue151515-2111111022194101561793403
Cost of Revenue3339-1213488326
Gross Profit-11-202815313577
R&D13314063633517351533992427
SG&A1615131745111283153765605475871,773857764
Tax0000000000
Net Income-1-02-17-6-300-43-139-392-507-1,704-524-565-1,642-1,438-1,334-2,343-1,805-864
Cash Flow ($'000)2011-12-312012-03-312012-06-302012-09-302012-12-312013-03-312013-06-302013-09-302013-12-312014-09-302014-12-312015-03-312015-09-302017-03-312017-06-302017-09-302017-12-312018-09-302018-12-312019-03-312019-06-302019-09-30
Cash Operating6-3611-5-20-4-299-466-581-1,017-1,016-729-1,150-1,751
Cash Investing0-500000000000177
Cash Financing10150500650-4665003,940-6-81,585696533